Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research led by the Nerlov Group in the Medical Research Council (MRC) Molecular Haematology Unit provides the first detailed explanation of how parasite-fighting immune cells are selectively increased following infection.

3D illustration of human immune cells - mast cell, basophil, eosinophil - involved in allergic reactions and inflammation.

The study, published in Nature, describes a complete pathway from parasite infection through to the chromatin-level changes that allow the organism to respond to it.

In collaboration with groups at the Kennedy Institute in Oxford, the Francis Crick Institute in London, the University of Sussex and Trinity College Dublin, researchers at the MRC Weatherall Institute of Molecular Medicine identified the molecular mechanisms that increase production of basophils, eosinophils and mast cells. These are myeloid cell types essential for the type 2 immune response against worms and other parasites. However, overproduction of these cells can cause allergic inflammation, asthma and mast cell disorders. So, this paper’s findings also revealed a potential drug target for treating these diseases.

Two pathways for innate immune cells

Myeloid cells are part of the innate immune system, which provides rapid, first-line defence against bacteria, viruses and parasites. For a long time, scientists believed all myeloid cells arose from a single common progenitor. However, previous work from the Nerlov Group demonstrated that there are in fact two distinct developmental routes: one that generates neutrophils and macrophages (mainly involved in the type 1 immune response against bacteria and viruses), and another that produces basophils, eosinophils and mast cells (critical for the type 2 immune response against parasite infection).

While the bacterial-response pathway has been extensively studied, far less was known about how the parasite-response pathway is regulated.

 

Read the full story on the Medical Research Council Weatherall Institute of Molecular Medicine (MRC WIMM) website.

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.